RPTX Insider Transactions
Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
---|---|---|---|---|---|---|---|---|
2024-03-28 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 110,049 | S-Sale | D | 2,650 | 4.62 | 12,243.00 |
2024-04-01 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 107,558 | S-Sale | D | 2,491 | 4.63 | 11,533.00 |
2024-03-28 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 45,564 | S-Sale | D | 825 | 4.62 | 3,812.00 |
2024-04-01 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 44,775 | S-Sale | D | 789 | 4.61 | 3,637.00 |
2024-03-28 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 72,318 | S-Sale | D | 450 | 4.64 | 2,088.00 |
2024-04-01 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 71,908 | S-Sale | D | 410 | 4.66 | 1,911.00 |
2024-03-28 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 231,709 | S-Sale | D | 500 | 4.64 | 2,320.00 |
2024-04-01 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 231,409 | S-Sale | D | 300 | 4.66 | 1,398.00 |
2024-03-25 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 43,862 | S-Sale | D | 825 | 4.79 | 3,952.00 |
2024-03-26 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 43,037 | S-Sale | D | 825 | 4.60 | 3,795.00 |
2024-03-27 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 42,212 | S-Sale | D | 825 | 4.62 | 3,812.00 |
2024-03-25 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 73,668 | S-Sale | D | 450 | 4.78 | 2,151.00 |
2024-03-26 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 73,218 | S-Sale | D | 450 | 4.61 | 2,074.00 |
2024-03-27 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 72,768 | S-Sale | D | 450 | 4.62 | 2,079.00 |
2024-03-25 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 233,209 | S-Sale | D | 500 | 4.78 | 2,390.00 |
2024-03-26 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 232,709 | S-Sale | D | 500 | 4.60 | 2,300.00 |
2024-03-27 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 232,209 | S-Sale | D | 500 | 4.62 | 2,310.00 |
2024-03-25 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 89,166 | S-Sale | D | 2,650 | 4.79 | 12,694.00 |
2024-03-26 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 86,516 | S-Sale | D | 2,650 | 4.64 | 12,296.00 |
2024-03-27 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 83,866 | S-Sale | D | 2,650 | 4.63 | 12,270.00 |
2024-03-01 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 85,000 | A-Award | A | 85,000 | 6.95 | 590,750.00 |
2024-03-01 | Forte Steve | officer: EVP, CHIEF FINANCIAL OFFICER | 44,687 | A-Award | A | 14,000 | 0.00 | 0.00 |
2024-03-01 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 85,000 | A-Award | A | 85,000 | 6.95 | 590,750.00 |
2024-03-01 | Zinda Michael | officer: EVP, CHIEF SCIENTIFIC OFFICER | 74,118 | A-Award | A | 14,000 | 0.00 | 0.00 |
2024-03-01 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 237,000 | A-Award | A | 237,000 | 6.95 | 1,647,150.00 |
2024-03-01 | Segal Lloyd Mitchell | director, officer: PRESIDENT AND CEO | 124,677 | A-Award | A | 40,000 | 0.00 | 0.00 |
2024-03-01 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 233,709 | A-Award | A | 14,000 | 0.00 | 0.00 |
2024-03-01 | Koehler Maria | officer: EVP, CHIEF MEDICAL OFFICER | 85,000 | A-Award | A | 85,000 | 6.95 | 590,750.00 |
2023-12-11 | Koehler Maria | officer: EVP, Chief Medical Officer | 219,709 | M-Exempt | A | 23,556 | 2.43 | 57,123.00 |
2023-12-11 | Koehler Maria | officer: EVP, Chief Medical Officer | 196,153 | M-Exempt | A | 20,190 | 2.06 | 41,632.00 |
2023-12-11 | Koehler Maria | officer: EVP, Chief Medical Officer | 87,691 | M-Exempt | D | 23,556 | 2.43 | 57,123.00 |
2023-12-11 | Koehler Maria | officer: EVP, Chief Medical Officer | 24,229 | M-Exempt | D | 20,190 | 2.06 | 41,632.00 |
2023-11-16 | BVF PARTNERS L P/IL | 10 percent owner | 5,309,432 | P-Purchase | A | 153,693 | 5.38 | 827,437.00 |
2023-11-15 | BVF PARTNERS L P/IL | 10 percent owner | 5,155,739 | P-Purchase | A | 493,337 | 5.00 | 2,466,636.00 |
2023-11-16 | BVF PARTNERS L P/IL | 10 percent owner | 4,308,573 | P-Purchase | A | 125,909 | 5.38 | 677,856.00 |
2023-11-15 | BVF PARTNERS L P/IL | 10 percent owner | 4,182,664 | P-Purchase | A | 390,507 | 5.00 | 1,952,496.00 |
2023-11-16 | BVF PARTNERS L P/IL | 10 percent owner | 548,938 | P-Purchase | A | 16,143 | 5.38 | 86,909.00 |
2023-11-15 | BVF PARTNERS L P/IL | 10 percent owner | 532,795 | P-Purchase | A | 47,712 | 5.00 | 238,555.00 |
2023-11-02 | BVF PARTNERS L P/IL | 10 percent owner | 4,662,402 | P-Purchase | A | 218,979 | 3.60 | 788,324.00 |
2023-11-02 | BVF PARTNERS L P/IL | 10 percent owner | 3,792,157 | P-Purchase | A | 492,251 | 3.60 | 1,772,104.00 |
2023-11-02 | BVF PARTNERS L P/IL | 10 percent owner | 485,083 | P-Purchase | A | 72,479 | 3.60 | 260,924.00 |
2023-06-08 | SCHAFER CAROL | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | RHOADS ANN D | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | Morrison Briggs | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | Molineaux Susan | director | 76,200 | A-Award | A | 76,200 | 11.66 | 888,492.00 |
2023-06-08 | Kulkarni Samarth | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | Foley Todd | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | Civik Thomas | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | Bonita David P | director | 27,200 | A-Award | A | 27,200 | 11.66 | 317,152.00 |
2023-06-08 | Molineaux Susan | director: | 0 | 0 | 0.00 | 0.00 | ||
2023-06-07 | Zinda Michael | officer: EVP, Chief Scientific Officer | 62,987 | S-Sale | D | 6,404 | 12.03 | 77,040.00 |
2023-06-08 | Zinda Michael | officer: EVP, Chief Scientific Officer | 60,118 | S-Sale | A | 2,869 | 12.02 | 34,485.00 |
2023-06-06 | Zinda Michael | officer: EVP, Chief Scientific Officer | 69,391 | S-Sale | D | 1,200 | 12.04 | 14,448.00 |
2023-01-30 | Zinda Michael | officer: EVP, Chief Scientific Officer | 97,100 | A-Award | A | 97,100 | 12.42 | 1,205,982.00 |
2023-01-30 | Zinda Michael | officer: EVP, Chief Scientific Officer | 70,591 | A-Award | A | 24,550 | 0.00 | 0.00 |
2023-01-30 | Koehler Maria | officer: EVP, Chief Medical Officer | 175,963 | A-Award | A | 26,450 | 0.00 | 0.00 |
2023-01-30 | Koehler Maria | officer: EVP, Chief Medical Officer | 119,250 | A-Award | A | 119,250 | 12.42 | 1,481,085.00 |
2023-01-30 | Segal Lloyd Mitchell | director, officer: President and CEO | 344,200 | A-Award | A | 344,200 | 12.42 | 4,274,964.00 |
2023-01-30 | Segal Lloyd Mitchell | director, officer: President and CEO | 84,677 | A-Award | A | 78,550 | 0.00 | 0.00 |
2023-01-30 | Forte Steve | officer: EVP, Chief Financial Officer | 111,050 | A-Award | A | 111,050 | 12.42 | 1,379,241.00 |
2023-01-30 | Forte Steve | officer: EVP, Chief Financial Officer | 30,687 | A-Award | A | 24,530 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 563,403 | J-Other | D | 287,157 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 65,957 | J-Other | A | 2,065 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 63,892 | J-Other | A | 1,866 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 62,026 | J-Other | A | 62,026 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 42,877 | J-Other | D | 21,854 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 25,131 | J-Other | A | 3,014 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 22,117 | J-Other | A | 1,240 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 18,761 | J-Other | D | 9,561 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 16,949 | J-Other | D | 8,638 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 4,721 | J-Other | A | 4,721 | 0.00 | 0.00 |
2022-12-29 | Jerel Davis | director | 0 | J-Other | D | 4,721 | 0.00 | 0.00 |
2022-12-20 | Koehler Maria | officer: EVP, Chief Medical Officer | 149,513 | M-Exempt | A | 51 | 2.43 | 123.70 |
2022-12-20 | Koehler Maria | officer: EVP, Chief Medical Officer | 149,462 | M-Exempt | A | 48,456 | 2.06 | 99,916.00 |
2022-12-20 | Koehler Maria | officer: EVP, Chief Medical Officer | 111,247 | M-Exempt | D | 51 | 0.00 | 0.00 |
2022-12-20 | Koehler Maria | officer: EVP, Chief Medical Officer | 44,419 | M-Exempt | D | 48,456 | 0.00 | 0.00 |
2022-12-09 | Jerel Davis | director | 2,094,451 | S-Sale | D | 250,000 | 16.00 | 4,000,000.00 |
2022-06-13 | LAMPERT MARK N | director: | 4,443,423 | P-Purchase | A | 74,666 | 12.73 | 950,498.00 |
2022-06-03 | Versant Vantage I, L.P. | 10 percent owner | 2,344,451 | S-Sale | D | 250,000 | 12.25 | 3,062,925.00 |
2022-06-03 | Versant Vantage I, L.P. | 10 percent owner | 1,464,875 | S-Sale | D | 438,795 | 12.25 | 5,375,985.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 850,560 | J-Other | D | 614,315 | 0.00 | 0.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 141,103 | J-Other | A | 4,419 | 0.00 | 0.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 136,684 | J-Other | A | 3,992 | 0.00 | 0.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 132,692 | J-Other | A | 132,692 | 0.00 | 0.00 |
2022-06-03 | Versant Vantage I, L.P. | 10 percent owner | 111,484 | S-Sale | D | 33,395 | 12.25 | 409,146.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 64,731 | J-Other | D | 46,753 | 0.00 | 0.00 |
2022-06-03 | Versant Vantage I GP-GP, LLC | director: | 48,776 | S-Sale | D | 14,611 | 12.25 | 179,010.00 |
2022-06-03 | Versant Vantage I, L.P. | 10 percent owner | 48,776 | S-Sale | D | 14,611 | 12.25 | 179,010.00 |
2022-06-03 | Versant Vantage I, L.P. | 10 percent owner | 44,065 | S-Sale | D | 13,199 | 12.25 | 161,710.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 28,322 | J-Other | D | 20,454 | 0.00 | 0.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 25,587 | J-Other | D | 18,478 | 0.00 | 0.00 |
2022-06-03 | Versant Vantage I GP-GP, LLC | director: | 25,587 | J-Other | D | 18,478 | 0.00 | 0.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 10,099 | J-Other | A | 10,099 | 0.00 | 0.00 |
2022-06-06 | Versant Vantage I, L.P. | 10 percent owner | 0 | J-Other | D | 10,099 | 0.00 | 0.00 |
2022-06-03 | Versant Ventures V, LLC | 10 percent owner | 2,344,451 | S-Sale | D | 250,000 | 12.25 | 3,062,925.00 |
2022-06-03 | Versant Ventures V, LLC | 10 percent owner | 1,464,875 | S-Sale | D | 438,795 | 12.25 | 5,375,985.00 |
2022-06-06 | Versant Ventures V, LLC | 10 percent owner | 850,560 | J-Other | D | 614,315 | 0.00 | 0.00 |
2022-06-06 | Versant Ventures V, LLC | 10 percent owner | 141,103 | J-Other | A | 4,419 | 0.00 | 0.00 |
2022-06-06 | Versant Ventures V, LLC | 10 percent owner | 136,684 | J-Other | A | 3,992 | 0.00 | 0.00 |
2022-06-06 | Versant Ventures V, LLC | 10 percent owner | 132,692 | J-Other | A | 132,692 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.